{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:19:11Z","timestamp":1790065151976,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaut.2025.103410","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T17:46:15Z","timestamp":1743529575000},"page":"103410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["T-bet+CD11c+ age-associated B cells resist BLyS- and CD20-targeted ablation in murine lupus models"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3523-0661","authenticated-orcid":false,"given":"James J.","family":"Knox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Futeran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Cataliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Cancro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103410_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2025.103410_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103410_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramskold","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaut.2025.103410_bib4","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103410_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2025.103410_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2025.103410_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.immuni.2020.03.020","article-title":"The transcription factor T-bet resolves memory B cell subsets with distinct tissue distributions and antibody specificities in mice and humans","volume":"52","author":"Johnson","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103410_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103410_bib9","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.4049\/jimmunol.1501209","article-title":"Age-associated B cells: a T-bet-dependent effector with roles in protective and pathogenic immunity","volume":"195","author":"Rubtsova","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103410_bib10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103410_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jama.1966.03100040091025","article-title":"NZB\/NZW mice as a model of systemic lupus erythematosus","volume":"195","author":"Dubois","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2025.103410_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-1229(90)90040-W","article-title":"Experimental induction of systemic lupus erythematosus by recognition of foreign Ia","volume":"57","author":"Morris","year":"1990","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.jaut.2025.103410_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.immuni.2012.09.007","article-title":"The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses","volume":"37","author":"Zhu","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103410_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2025.103410_bib15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2011-01-330530","article-title":"A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice","volume":"118","author":"Hao","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2025.103410_bib16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2025.103410_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies","volume":"24","author":"Treon","year":"2001","journal-title":"J. Immunother."},{"key":"10.1016\/j.jaut.2025.103410_bib18","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103410_bib19","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.4049\/jimmunol.1101629","article-title":"An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus","volume":"187","author":"Ahuja","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103410_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.41608","article-title":"The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model","volume":"73","author":"Marinov","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103410_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T06:22:51Z","timestamp":1746166971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":21,"alternative-id":["S0896841125000551"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103410","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-bet+CD11c+ age-associated B cells resist BLyS- and CD20-targeted ablation in murine lupus models","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103410"}}